Welcome to Conformetrix
Conformetrix is a drug discovery company at the cutting-edge of ligand-based design. We develop new drugs by copying the templates provided by other bioactive ligands.
Our platform technology is a
powerful set of analytical tools that
can record the dynamic range of motion that molecules explore in
solution with extremely high precision. We call this data a
molecules' 4D-structure. By
analysing this structure we can
identify the bioactive shape of any optimised ligand. This is
a
true world first. It finally realises an entirely new and
complementary strategy to high-throughput screening that works for any
disease target.
Our unique competitive
advantage is in being able to copy Mother
Nature’s own "blockbuster blueprints": the peptide
hormones and other natural signalling molecules that regulate
the
human body's functions. These ligands have been
optimised over millions of years of evolution to be
highly
potent yet highly target-specific - the perfect profile for a
therapeutic drug.
December 2009
Meet Conformetrix at the Genesis meeting in London (10-11 Dec).
September 2009
Conformetrix appoints Dr Sam Williams (CEO of Modern Biosciences) as a non-exec director.
July 2009
Conformetrix scientists publish work on the alpha-7 nicotinic receptor in collaboration with scientists at Oxford, Kinki and Kyoto Universities.
April 2009
Conformetrix is awarded a prestigous GRAND award for innovative
R&D
by the NWDA..
March 2009
Conformetrix launches its new virtual screening service at the EuroCUP computational chemistry workshop in Toledo, Spain.
December 2008
Conformetrix wins the Bionow Start-up of the Year (2008) Award.